CRDN

Views & Analysis

The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.

Views & Analysis

CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.